These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2958861)

  • 1. Treatment of prostatic cancer with cyproterone acetate as monotherapy.
    Beurton D; Grall J; Davody P; Cukier J
    Prog Clin Biol Res; 1987; 243A():369-77. PubMed ID: 2958861
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U
    Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of virginal prostatic cancer with cyproterone acetate].
    Maier U
    Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
    Properzi G; Francavilla S; Vicentini C; Cordeschi G; Galassi P; Paradiso Galatioto G; Miano L
    Eur Urol; 1989; 16(6):426-32. PubMed ID: 2531668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyproterone acetate as monotherapy in prospective randomized trials.
    de Voogt HJ
    Prog Clin Biol Res; 1990; 359():85-91; discussion 105-7. PubMed ID: 2149459
    [No Abstract]   [Full Text] [Related]  

  • 6. Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
    Tunn UW; Goldschmidt AJ; Peter K; Becker M
    Prog Clin Biol Res; 1990; 359():165-76; discussion 177-80. PubMed ID: 2149458
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
    Tauveron I; Hermabessière J
    Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chemotherapy of advanced prostate cancer].
    Hofmann W; Langkopf B
    Z Urol Nephrol; 1986 Jan; 79(1):33-9. PubMed ID: 2938361
    [No Abstract]   [Full Text] [Related]  

  • 9. Is there a best endocrine management of prostatic carcinoma?
    Robinson MR
    Prog Clin Biol Res; 1988; 269():147-58. PubMed ID: 2969114
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
    Aubert J; Dore B; Irani J; Bon D
    J Urol (Paris); 1990; 96(8):431-5. PubMed ID: 1707083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyproterone acetate in the management of prostatic cancer.
    Tunn UW
    Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
    Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
    Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
    [No Abstract]   [Full Text] [Related]  

  • 13. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
    Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
    Di Silverio F; Serio M; Costantini A
    J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J
    Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects of cyproterone acetate on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
    Varenhorst E; Karlberg BE; Risberg B; Wallentin L; Wranne B
    Urologe A; 1981 Jul; 20(4):218-22. PubMed ID: 6455834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF; Schröder H; el Etreby MF; Neumann F
    Prog Clin Biol Res; 1988; 260():63-75. PubMed ID: 2966407
    [No Abstract]   [Full Text] [Related]  

  • 19. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with cyproterone acetate in a randomised and in an open trial.
    Tunn UW; Weiglein W; Saborowski J; Senge T
    Prog Clin Biol Res; 1987; 243A():365-8. PubMed ID: 2958860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.